Pseudogout Associated Hip Pain in a Patient with HIV Infection by Dala-Ali, Benan M. et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2010, Article ID 842814, 4 pages
doi:10.1155/2010/842814
Case Report
Pseudogout Associated Hip Pain in a Patient with HIV Infection
Benan M.Dala-Ali,1 Matthew Welck,1 Mary AnneLloyd,2 and Henry D. Atkinson1
1North Middlesex University Hospital, Sterling Way, London N18 1QX, UK
2Watford General Hospital, Hertfordshire WD18 0HB, UK
Correspondence should be addressed to Benan M. Dala-Ali, benan@doctors.org.uk
Received 26 August 2010; Accepted 3 November 2010
Academic Editor: Ingo W. Husstedt
Copyright © 2010 Benan M. Dala-Ali et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
HIV infection is a global pandemic, currently aﬀecting approximately 77,000 people in the UK and 33 million people around the
world. The infection has widespread eﬀects on the body and can involve the musculoskeletal system. It is therefore important
that orthopaedic surgeons are aware of the condition and its sequelae. We present the case of a 46-year-old man with a 10-year
historyof HIV who presented with acute hip pain, diﬃcultyweight-bearing, and constitutionalsymptoms.Following radiological,
microbiological, and serological tests a diagnosis of pseudogout was established following microscopic analysis of the hip joint
aspirate. The patient’s symptoms resolved completely following the joint aspiration and NSAID therapy. Studies have shown
a relationship between HIV infection and gout. The virus has also been linked to osteonecrosis, osteopenia, bone and joint
tuberculosis, and septic arthritis from rare pathogens. However, it is diﬃcult to fully ascertain whether these conditions are related
to the HIV infection itself or the HAART (highly active antiretroviral therapy). There are no previously reported cases of HIV-
infected patients with pseudogout. The case is discussed with reference to the literature.
1.Background
HIV infection is a global pandemic which in 2007 aﬀected
77,000 people in the UK and 33 million people around
the world, according to the World Health Organisation
[1]. The infection has widespread systemic eﬀects which
include the musculoskeletal system. It is thus essential that
orthopaedic surgeons are aware of the condition and its
sequelae.
Antiretroviral therapies, ﬁrst licensed in 1995, have
altered the course of HIV and its manifestations. However,
these drugs are also known to have a multitude of side eﬀects
including osteonecrosis and metabolic abnormalities.
We report the case of an HIV patient presenting with
spontaneous non-traumatic hip pain, who following radio-
logical, microbiological, and serological tests was diagnosed
as suﬀering from pseudogout. This is the ﬁrst reported case
of an HIV-infected patient with hip pseudogout. The case is
discussed in the context of HIV and other causes of acute
joint pain.
2.CaseReport
A 55-year-old HIV-positive Caucasian man presented with
a one-day history of spontaneous-onset left hip pain. The
patient described a similar episode in the contralateral hip
in 1997, which had resolved with analgesia and rest.
He had been diagnosed with HIV in 2002 and was
immediately commenced on “highly active antiretroviral
therapy” (HAART) to control disease progression. His HIV
treatment consisted of two nucleoside reverse transcriptase
inhibitors (emtricitabine and tenofovir) given as a ﬁxed-
dose combination (Truvada 200/245) once per day and the
protease inhibitor duranavir 800mg boosted with ritonavir
100mg once per day. The patient also had a history of
hypercholesterolaemia and syphilis. He was a non-smoker
and an infrequent drinker.
On presentation he was mildly pyrexial and was unable
to weight-bear through pain. There was a reduced range of
both active and passive left hip movement (20–75 degrees
ﬂexion and 10-0-10 degrees of rotation), and it was held2 Case Reports in Medicine
in 30 degrees of ﬂexion at rest. Other musculoskeletal and
neurological examinations were essentially normal. Blood
investigations initially founda normal whiteblood cellcount
(WCC) of 8.3 × 109/L, C-reactive protein (CRP) of <3U/L,
erythrocyte sedimentation rate (ESR) of 10mm/hr, Creatine
Kinase (CK) of 88U/L (normal 25–150U/L), and negative
ANA and ANCA.
Plain radiographs of the pelvis demonstrated only mild
bilateral osteoarthritis (see Figure 1).
The patient was admitted under the HIV physicians for
bed rest, analgesia, and observation; however he did not
improve. Over the subsequent two days his CRP increased to
109, ESR to 90, though his white cells remained stable (WCC
of 8.1×109/L). An MRI scan revealed a large left hip eﬀusion
and a moderate right hip eﬀusion (see Figure 2).
An aspiration of the left hip was performed under local
anaesthetic and revealed a turbid yellow ﬂuid, which was
sent for microbiology and cytology. A diﬀerential count of
the aspirate showed 95% neutrophils, and gram staining
found no bacteria present. Microscopy revealed positively
birefringentcrystals,consistentwithcalciumpyrophosphate.
A diagnosis of hip pseudogout was made and the patient was
commenced on high-dose nonsteroidal anti-inﬂammatory
drugs (NSAIDs). The patient improved clinically over the
next 48 hours and was discharged home fully weight-
bearing. He was followed up in both the orthopaedic and
rheumatology clinics, where the latter excluded any other
major risk factors for the development of pseudogout. He
remained well at 6-month review.
3. Discussion
HIV has been linked with a variety of orthopaedic and
rheumatological conditions. The ﬁrst documented associ-
ation in 1987 was between AIDS and Reiter’s Syndrome,
followed by gout, osteoporosis, avascular necrosis, septic
arthritis, osteomyelitis, and tuberculosis [2].
30%–40% of HIV/AIDS patients suﬀer from arthralgia.
Though this can aﬀect any joint, the knees, shoulders, and
elbows are most commonly aﬀected. When presented with
such a patient, the orthopaedic surgeon must be aware of the
possible diﬀerential diagnoses.
3.1. Gout. Gout is estimated to aﬀect around 0.5% of
HIV/AIDS patients per year [3, 4]. These patients often
have urate abnormalities, 41% with hyperuricaemia and 5%
with hypouricaemia, unlike HIV-negative patients whose
urate levels are usually normal [5]. The elevated urate
is likely to be the result of the HAART treatment itself
[6–8] rather than of the HIV infection, and drugs such
as the protease inhibitor ritonavir are known to have
this association [9]. There are several hypotheses for why
HAART might cause hyperuricaemia. The drugs may cause
mitochondrial toxicity, which can increase the formation of
lactate, which then competes with urate for tubular secretion
in the kidneys. HAART drugs may also cause a respiratory
chain failure that results in ATP depletion, which then
increasesurateproductioninthepurinenucleotidecycle[10,
11]. Thirdly, HAART drugs cause hyperlipidaemia, insulin
Figure 1: X-ray at admission.
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Figure 2: T2 weighted MRI scan of the pelvis.
resistance, and central adiposity, which in turn can lead to
gout.
3.2. Pseudogout. Despite the association between gout and
HIV, there have been no documented cases of pseudogout-
associated arthralgia. Whilst most cases of pseudogout
are idiopathic, there are relationships with trauma, aging,
and metabolic diseases, including hyperparathyroidism and
haemochromatosis.Calciumpyrophosphatecrystalsinpseu-
dogout are thought to develop from an increased adeno-
sine triphosphate breakdown, which can lead to increased
pyrophosphate levels in the joint [12].
It is diﬃcult to know whether the HIV infection or
HAART therapy was directly responsible for the pseudogout
or whether it was secondary to another condition. Studies
have shown a link between HIV or HAART and hypophos-
phatemia [13], hyperparathyroidism [14], hypothyroidism
[15], and hypercalcaemia [16]. All these conditions are
known risk factors of pseudogout.
3.3. Septic Arthritis. Septic arthritis usually presents with
a short history of joint pain and fever, with a raisedCase Reports in Medicine 3
ESR and an absence of peripheral leukocytosis. It is more
prevalent in HIV/AIDS patients that are intravenous drug
users or haemophiliacs [17, 18], and the majority resolve
with appropriate intravenous antibiotics [5]. However, if
the patient fails to improve on the antibiotics, an open
drainage of the joint should be performed in theatre. The
most common pathogens are Staphylococcus aureus (60%)
and Candida albicans (20%), and rarely pathogens such as
Stenotrophomonas maltophilia and Proteus wickerhamii [19].
3.4. Tuberculosis. There has been a dual global epidemic
of tuberculosis (TB) and HIV/AIDS. The World Health
Organisation estimated that there were 9.27 million new
cases of TB in 2007 (139 per 100,000 population); of these
1.37 million (14.8%) were HIV positive. The two conditions
are interlinked, as the HIV-virus speciﬁcally eliminates
macrophages and CD4 lymphocytes, which are cells essential
for the prevention of active tuberculosis.
There has been an increased incidence of extrapul-
monary TB, including bone and joint TB, in HIV/AIDS
patients [20]. The diagnosis of skeletal TB is often delayed
in developed countries, as it is not commonly encountered.
The most common site of musculoskeletal TB among
HIV/AIDS patients is the spine (Pott’s spine) [5]. The infec-
tion can also aﬀect the weight-bearing joints, in particular
the knee and hip. It presents with chronic pain with minimal
inﬂammation. TBosteomyelitis classicallypresentswithpain
and swelling of the bone and surrounding soft tissues. There
may also be enlarged regional lymphadenopathy or the
presence of an abscess or sinus.
3.5. Osteopenia/Osteoporosis. HAART causes metabolic
changes in the body and has been shown to cause osteopenia
and osteoporosis, putting patients at risk of low-energy
fractures. A study of 600 HIV-infected individuals on
antiretroviral therapy demonstrated a signiﬁcantly higher
prevalence of osteopenia compared to the national average
in the US [21].
The underlying mechanism of bone loss in HIV-infected
patients is not fully understood. Studies using markers of
bone formation and resorption have shown an uncoupling
of these events in individuals with HIV infection [22]. Other
studies have found an increased number of proinﬂammatory
cytokines tumour necrosis factor (TNF) and interleukin-6
(IL-6)intheHIV-infectedpatients,whichhaveanimportant
role in osteoclast activation and resorption [23].
3.6. Osteonecrosis. HIV/AIDs patients have an increased risk
of developing osteonecrosis, believed to occur as a result
of a vascular thrombosis, caused either by the actions of
anticardiolipin antibodies or by a deﬁciency of protein S
[24]. A study using magnetic resonance imaging (MRI) of
339 HIV-positive patients found that 4.4% suﬀered from
asymptomatic osteonecrosis [25]. It is unclear whether this
is the result of the HIV virus, the HAART treatment, or
an increased appreciation of osteonecrosis on scans. The
protease inhibitor drugs have been speciﬁcally reported to
lead to osteonecrosis [26, 27].
4. Conclusion
HIV/AIDS is a global phenomenon and it is essential that
clinicians are aware of its widespread eﬀects and those of
its drug treatments. This is the ﬁrst documented case of hip
pseudogout in an HIV/AIDS patient. Though it is unclear
whether this was the result of the HIV infection, the HAART
treatment, or an unrelated cause, the cases highlight the
diagnostic diﬃculties one can encounter in these susceptible
patients.
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